Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Above 200 Day Moving Average of $1.13

Atossa Therapeutics, Inc. (NASDAQ:ATOSGet Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.13 and traded as high as $1.55. Atossa Therapeutics shares last traded at $1.46, with a volume of 1,163,998 shares.

Analysts Set New Price Targets

ATOS has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a report on Tuesday, May 14th. HC Wainwright upped their price target on Atossa Therapeutics from $4.00 to $6.00 and gave the company a “buy” rating in a report on Monday, May 13th. Finally, raised Atossa Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th.

Read Our Latest Stock Report on ATOS

Atossa Therapeutics Stock Performance

The firm has a market capitalization of $183.61 million, a price-to-earnings ratio of -6.08 and a beta of 1.27. The firm’s 50-day moving average price is $1.63 and its two-hundred day moving average price is $1.13.

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. As a group, equities research analysts anticipate that Atossa Therapeutics, Inc. will post -0.23 EPS for the current year.

Insider Transactions at Atossa Therapeutics

In other Atossa Therapeutics news, Director Jonathan Finn bought 25,000 shares of Atossa Therapeutics stock in a transaction dated Wednesday, April 10th. The shares were acquired at an average cost of $1.77 per share, with a total value of $44,250.00. Following the acquisition, the director now directly owns 25,000 shares of the company’s stock, valued at $44,250. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Atossa Therapeutics in the third quarter worth about $98,000. PFG Investments LLC bought a new position in Atossa Therapeutics in the 1st quarter worth approximately $43,000. Vanguard Group Inc. lifted its holdings in Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after buying an additional 78,269 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Atossa Therapeutics in the 1st quarter valued at $151,000. 12.74% of the stock is owned by institutional investors.

Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Read More

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with's FREE daily email newsletter.